Source: Pharamceutical Technology

Calliditas Therapeutics: Calliditas IPO raises $90m to support rare disease pipeline

Sweden-based biotech Calliditas Therapeutics has closed its initial public offering (IPO) on the Nasdaq global select market. The IPO involved...Read More...The post Calliditas IPO raises $90m to support rare disease pipeline appeared first on Pharmaceutical Technology.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Renee Aguiar-Lucander's photo - CEO of Calliditas

CEO

Renee Aguiar-Lucander

CEO Approval Rating

90/100

Calliditas is a pharmaceutical company that develops and commercializes therapeutics for the treatment of inflammatory kidney diseases. Read more